Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNOW: S-1 + nab-paclitaxel + oxaliplatin in advanced gastric cancer
jRCTs011180022Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Feb 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur, nab-paclitaxel and oxaliplatin in gastric adenocarcinoma, sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Maximum tolerated dose (MTD), Recommended dose (RD) and 1 more. Started Feb 2016; status: completed.
02
Drugs
tegafurnab-paclitaxeloxaliplatin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on jRCTs011180022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011180022.